This content is from: Home

Pfizer’s arrival at patent cliff elicits concern from Congress

Pfizer yesterday became the latest major pharmaceutical manufacturer to see a leading drug patent expire with the introduction of generic versions of Lipitor - and now the company’s strategy for coping with the revenue loss has raised eyebrows in Congress

To access our in-house intelligence please request a trial here.

Read this article – and more – for a 30 day period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Related

Instant access to all of our content. Membership Options | 30 Day Trial